News tagged with avastin
Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer, too. Two studies found it did not improve survival for most of these patients and kept their ...
Cancer Dec 28, 2011 | 4.3 / 5 (4) | 1
Surprising results from two new studies may reopen debate about the value of Avastin for breast cancer. The drug helped make tumors disappear in certain women with early-stage disease, researchers found.
Cancer Jan 25, 2012 | 5 / 5 (2) | 0
A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.
Cancer Apr 19, 2013 | 5 / 5 (2) | 0 |
(AP) -- Regulators on Friday approved Regeneron Pharmaceuticals Inc.'s drug Eylea, an injection designed to treat a common cause of blindness in older people.
Medications Nov 19, 2011 | 5 / 5 (1) | 5
Cancer treatments designed to block the growth of blood vessels were found to increase the number of cancer stem cells in breast tumors in mice, suggesting a possible explanation for why these drugs don't ...
Cancer Jan 25, 2012 | 5 / 5 (1) | 1 |
(AP) -- The discovery that a fake version of the widely used cancer medicine Avastin is circulating in the United States is raising new fears that the multibillion-dollar drug-counterfeiting trade is increasingly ...
Medications Feb 16, 2012 | 5 / 5 (1) | 1
(AP) -- The news this week that a fake version of the cancer medicine Avastin has made its way into the United States highlights a longtime concern: There are few safeguards to make sure fake drugs can be ...
Medications Feb 16, 2012 | 5 / 5 (1) | 0
(AP) -- Counterfeit versions of the popular cancer drug Avastin obtained by European regulators contain a variety of chemicals, but not the active ingredient found in the genuine drug, according to drugmaker Roche.
Medications Feb 28, 2012 | 5 / 5 (1) | 0
The Food and Drug Administration is warning U.S. doctors about another counterfeit version of the cancer drug Avastin, the third case involving the best-selling Roche drug in the past year.
Medications Feb 06, 2013 | 5 / 5 (1) | 0
(AP) -- Drug maker Novartis says it is taking legal action in Britain to make hospitals use an eye drug that costs 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).
Medications Apr 24, 2012 | 1 / 5 (1) | 0
Bevacizumab (trade name Avastin, Genentech/Roche) is a monoclonal antibody that recognises all vascular endothelial growth factor (VEGF) isoforms. It is used in the treatment of cancer, where it inhibits tumor growth by blocking the formation of new blood vessels (angiogenesis). Bevacizumab was the first clinically available angiogenesis inhibitor in the United States.
Bevacizumab is currently approved by the U.S. Food and Drug Administration (FDA) for cancers that are metastatic (have spread to other parts of the body). It received its first approval in 2004 was for combination use with standard chemotherapy for metastatic colon cancer and non-small cell lung cancer. In 2008, it was approved by the FDA for use in metastatic breast cancer, a decision that generated some controversy as it went against the recommendation of its advisory panel, who objected because it only slowed tumor growth but failed to extend survival.
Clinical studies are underway in non-metastatic breast cancer, renal cell carcinoma, glioblastoma multiforme, ovarian cancer, castrate-resistant (formally called hormone refractory) prostate cancer, non-metastatic unresectable liver cancer and metastatic or unresectable locally advanced pancreatic cancer. A study released in April 2009 found that bevacizumab is not effective at preventing recurrences of non-metastatic colon cancer following surgery. In May 2009, it received FDA approval for treatment of reoccurring Glioblastoma Multiforme, while treatment for initial growth is still in phase III clinical trial.
For more information about Bevacizumab, read the full article at
This text uses material from Wikipedia and is available under the GNU Free Documentation License.